(Q37811878)

23 August 2017

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia (English)

1 reference

23 August 2017

chronic myeloid leukemia

0 references

1 reference

D Bixby

1

1 reference

PubMed ID

21102425

23 August 2017

M Talpaz

series ordinal

2

1 reference

23 August 2017

19 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

25

1 reference

23 August 2017

7-22

1 reference

23 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2010.238

23 August 2017

0 references

cites work

Current trends in the management of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Getting to the stem of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Critical role for Gab2 in transformation by BCR/ABL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Leukaemogenesis: more than mutant genes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Current role of stem cell transplantation in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Role of allo-SCT for CML in 2010.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Aurora kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.238

7 January 2021

Identifiers

DOI

10.1038/LEU.2010.238

1 reference

23 August 2017

1 reference

PubMed ID

21102425